ophthalmologytimes6h
ACELYRIN announces phase 2b/3 trial of izokibep did not meet primary endpoint, ceases further additional internal investment
The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.
Health Affairs2d
FDA Breakthrough Device Designation: Clinical Evidence And Medicare Payment Policies
Devices that are approved through a process that does not require any clinical evidence for FDA authorization should not ...
360dx2d
With New Validation Study, FDA Approval, Prenosis Prepares for Clinical Use of AI-Based Sepsis Tool
The firm also has plans for tests beyond sepsis, including for cardiac events and other conditions that are commonly treated in acute care settings.
Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates
Omeros' stock is volatile, driven by the potential FDA approval of narsoplimab for HSCT-TMA, despite past setbacks including ...
Too Old to Operate3d
Efficacy of Guselkumab in LN Falls Short of Expectations in Clinical Study
The following is a summary of “Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a ...
DBV stock rallies post-market on FDA Viaskin update
DBV Technologies (DBVT) stock shot up 29% in post-market after the company said it has aligned with the FDA on an accelerated approval pathway for its peanut allergy patch Viaskin.
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 ...
precisionmedicineonline3d
Adaptive Biotechnologies' MRD Test May Allow Some Mantle Cell Lymphoma Patients to Skip Transplant
A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...
Cancer Research3d
About the Journal
Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol ...
New path toward faster drug approvals for multiple myeloma treatment
A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...